Efficacy and Safety of a Topical Skincare Regimen with Tripeptide/Hexapeptide following Aesthetic Procedures: Analysis of Two Randomized, Split-Face Trials in Asian Subjects - Report - MDSpire
Advertisement
Efficacy and Safety of a Topical Skincare Regimen with Tripeptide/Hexapeptide following Aesthetic Procedures: Analysis of Two Randomized, Split-Face Trials in Asian Subjects
Effectiveness and Safety of a Tripeptide/Hexapeptide-Based Topical Skincare Routine
Overview
This study evaluated the efficacy and safety of a facial serum containing TriHex Technology® compared to a basic moisturizer for skin recovery following fractional CO2 laser and radiofrequency microneedling in Asian participants.
Background
Periprocedural skincare is essential for minimizing downtime and enhancing recovery after energy-based device treatments, particularly in Asian populations where the risk of postinflammatory hyperpigmentation is heightened. The use of TriHex Technology® has been proposed to support extracellular matrix remodeling.
Data Highlights
No numerical data was provided in the source material.
Key Findings
The serum-treated side showed significantly greater recovery on several parameters after multiplicity correction.
High subject satisfaction was reported with the serum treatment.
Benefits were observed across multiple time points.
Other findings showed a consistent direction of effect but did not retain significance after correction.
Further controlled studies are warranted.
Clinical Implications
The findings indicate that a topical serum containing TriHex Technology® may have a role in skin recovery following aesthetic procedures in Asian populations.
Conclusion
The study indicates the need for further investigation into the efficacy of the TriHex Technology® serum for skin recovery after aesthetic treatments.
by Zhenfeng Liu, Zhen Yi, Peng Wang, Li Wan, Li Ye, Yijing Chen, Yiping Zhong, Mengting Qiu, Linshan Wu, Li Fan, Xiaoyan Fu, Alan D. Widgerow, Yuanmeng Yang, Céline Blanché, Bin Yang
Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
